Cáncer de mama metastásico

1. Guías de la ESMO

2. Visión personal

Ensayos Clínicos Relevantes

Quimioterapia

1. Quimioterapia secuencial versus concomitante - E1193

- Sledge GW, Neuberg D, Bernardo P, et al. Phase III Trial of Doxorubicin, Paclitaxel, and the Combination of Doxorubicin and Paclitaxel as Front-Line Chemotherapy for Metastatic Breast Cancer: An Intergroup Trial (E1193). J Clin Oncol 2003 21: 588-592

2. Adición de Bevacizumab a quimioterapia - E2100

- Miller K, Wang M, Gralow J, et al. Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer. N Engl J Med 2007 357: 2666-2676

3. Docetaxel + Capecitabina en primera línea

- O'Shaughnessy J, Miles D, Vukelja S, et al. Superior Survival With Capecitabine Plus Docetaxel Combination Therapy in Anthracycline-Pretreated Patients With Advanced Breast Cancer: Phase III Trial Results. J Clin Oncol 2002 20: 2812-2823

4. Gemcitabina + Paclitaxel en primera línea - GemPacMBC

- Albain KS, Nag SN, Calderillo-Ruiz G, et al. Gemcitabine Plus Paclitaxel Versus Paclitaxel Monotherapy in Patients With Metastatic Breast Cancer and Prior Anthracycline Treatment. J. Clin. Oncol. Aug 20, 2008; 26: 3950-3957

Anti HER2

1. Pivotal trial en HER2 positivo - primera línea

- Slamon DJ, Leyland-Jones B, Shak S, et al. Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2. N Engl J Med 2001 344: 783-792

2. Lapatinib + Capecitabina

- Geyer CE, Forster J, Lindquist D et al. Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer. N Engl J Med 2006 355: 2733-2743